title: Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma.
abstract: Background. In lung adenocarcinoma, the frequency of KRAS mutations is ethnicity dependent with a higher proportion in African Americans and white Caucasians than in Asians. The prevalence of these mutations among North Africans patients is unknown. The objective of this study was to report the frequency and spectrum of KRAS mutations in a group of Moroccan lung adenocarcinoma patients. Methods. Tumor specimens from 117 Moroccan patients with lung adenocarcinoma were selected to determine frequency and spectrum of KRAS mutations. KRAS mutations in codons 12 and 13 of exon 2 were analyzed using conventional DNA sequencing. Results. The overall frequency of the KRAS mutations was 9% (11/117). In the population with KRAS mutations, there was a trend towards more male (P = 0.06) and more smokers (P = 0.08) compared to patients with wild type KRAS. KRAS mutations were located at codon 12 in 10 out of 11 patients (91%). The G12C mutation was the most frequent KRAS mutation (73%). Conclusion. This is the first study to date examining the frequency and spectrum of KRAS mutations in lung adenocarcinomas in North African and Arab populations. KRAS mutation frequency in Moroccan patients was comparable with the frequency observed in East-Asian population. KRAS mutations are more likely observed in males and smokers and to be transversions. Further studies, in larger numbers of patients, are needed to confirm these findings.
authors.affiliation: Medical Oncology Department, National Institute of Oncology, Allal Elfassi Street, 62000 Rabat, Morocco.
authors.forename: Ibrahim
authors.identifier: 0000-0001-9645-5605
authors.initials: I
authors.lastname: Elghissassi
authors.affiliation: Medical Oncology Department, National Institute of Oncology, Allal Elfassi Street, 62000 Rabat, Morocco.
authors.forename: Hanane
authors.initials: H
authors.lastname: Inrhaoun
authors.affiliation: Medical Oncology Department, National Institute of Oncology, Allal Elfassi Street, 62000 Rabat, Morocco.
authors.forename: Anwar
authors.initials: A
authors.lastname: Boukir
authors.affiliation: Pathology Department, Nations-Unies Pathology Center, Rabat, Morocco.
authors.forename: Fouad
authors.initials: F
authors.lastname: Kettani
authors.affiliation: Pathology Department, Hassan Pathology Center, Rabat, Morocco.
authors.forename: Lamia
authors.initials: L
authors.lastname: Gamra
authors.affiliation: Pathology Department, Agdal Pathology Center, Rabat, Morocco.
authors.forename: Amina
authors.initials: A
authors.lastname: Mestari
authors.affiliation: Pathology Department, Casapath Pathology Center, Casablanca, Morocco.
authors.forename: Lamia
authors.initials: L
authors.lastname: Jabri
authors.affiliation: Medical Oncology Department, National Institute of Oncology, Allal Elfassi Street, 62000 Rabat, Morocco.
authors.forename: Youssef
authors.initials: Y
authors.lastname: Bensouda
authors.affiliation: Medical Oncology Department, National Institute of Oncology, Allal Elfassi Street, 62000 Rabat, Morocco.
authors.forename: Hind
authors.initials: H
authors.lastname: Mrabti
authors.affiliation: Medical Oncology Department, National Institute of Oncology, Allal Elfassi Street, 62000 Rabat, Morocco.
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: Drugs. 2012 Jun 19;72 Suppl 1:28-36
references.pmid: 22712795
references.citation: J Thorac Oncol. 2010 Nov;5(11):1734-40
references.pmid: 20881644
references.citation: Cancer. 2001 Sep 15;92(6):1525-30
references.pmid: 11745231
references.citation: Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):841-7
references.pmid: 9332768
references.citation: Nature. 2008 Oct 23;455(7216):1069-75
references.pmid: 18948947
references.citation: Am J Clin Oncol. 2014 Apr;37(2):144-7
references.pmid: 23211219
references.citation: Lung Cancer. 2008 Jan;59(1):111-8
references.pmid: 17904685
references.citation: Cell Oncol (Dordr). 2012 Jun;35(3):189-96
references.pmid: 22528563
references.citation: Oncol Lett. 2013 Nov;6(5):1207-1212
references.pmid: 24179496
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1405-12
references.pmid: 12433719
references.citation: Cancer Res. 1989 Sep 1;49(17):4682-9
references.pmid: 2547513
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Cancer. 2006 May 15;106(10):2200-7
references.pmid: 16598760
references.citation: Lung Cancer. 2010 Sep;69(3):272-8
references.pmid: 20022659
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5620-6
references.pmid: 19786660
references.citation: Br J Cancer. 2006 Jan 30;94(2):318-22
references.pmid: 16421597
references.citation: BMJ Open. 2013 Apr 03;3(4):
references.pmid: 23558737
references.citation: J Thorac Oncol. 2011 Jan;6(1):28-31
references.pmid: 21107288
references.citation: Clin Cancer Res. 2008 Sep 15;14(18):5731-4
references.pmid: 18794081
references.citation: Oncol Rep. 2007 Sep;18(3):623-8
references.pmid: 17671710
references.citation: J Thorac Oncol. 2013 May;8(5):530-42
references.pmid: 23524403
references.citation: Oncogene. 1998 Sep 17;17(11 Reviews):1395-413
references.pmid: 9779987
references.citation: J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210
references.pmid: 10413421
references.citation: Nat Rev Cancer. 2007 Apr;7(4):295-308
references.pmid: 17384584